Morgan Stanley’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-89,075
| Closed | -$330K | – | 6840 |
|
|
2017
Q4 | $330K | Buy |
89,075
+28,692
| +48% | +$106K | ﹤0.01% | 5198 |
|
|
2017
Q3 | $247K | Buy |
60,383
+14,581
| +32% | +$59.6K | ﹤0.01% | 5249 |
|
|
2017
Q2 | $170K | Sell |
45,802
-57,986
| -56% | -$215K | ﹤0.01% | 5417 |
|
|
2017
Q1 | $430K | Buy |
103,788
+102,562
| +8,366% | +$425K | ﹤0.01% | 4930 |
|
|
2016
Q4 | $5K | Sell |
1,226
-1,377
| -53% | -$5.62K | ﹤0.01% | 6283 |
|
|
2016
Q3 | $25K | Sell |
2,603
-4,838
| -65% | -$46.5K | ﹤0.01% | 5851 |
|
|
2016
Q2 | $42K | Buy |
7,441
+1,240
| +20% | +$7K | ﹤0.01% | 5583 |
|
|
2016
Q1 | $48K | Sell |
6,201
-6,451
| -51% | -$49.9K | ﹤0.01% | 5624 |
|
|
2015
Q4 | $168K | Buy |
12,652
+9,027
| +249% | +$120K | ﹤0.01% | 5171 |
|
|
2015
Q3 | $60K | Sell |
3,625
-35,674
| -91% | -$590K | ﹤0.01% | 5660 |
|
|
2015
Q2 | $882K | Buy |
39,299
+27,980
| +247% | +$628K | ﹤0.01% | 4301 |
|
|
2015
Q1 | $111K | Buy |
11,319
+1,942
| +21% | +$19K | ﹤0.01% | 5487 |
|
|
2014
Q4 | $107K | Sell |
9,377
-4,314
| -32% | -$49.2K | ﹤0.01% | 5521 |
|
|
2014
Q3 | $159K | Sell |
13,691
-13,011
| -49% | -$151K | ﹤0.01% | 5261 |
|
|
2014
Q2 | $519K | Sell |
26,702
-27,008
| -50% | -$525K | ﹤0.01% | 4545 |
|
|
2014
Q1 | $963K | Buy |
53,710
+46,141
| +610% | +$827K | ﹤0.01% | 4015 |
|
|
2013
Q4 | $80K | Sell |
7,569
-10,429
| -58% | -$110K | ﹤0.01% | 5428 |
|
|
2013
Q3 | $224K | Sell |
17,998
-42,541
| -70% | -$529K | ﹤0.01% | 4811 |
|
|
2013
Q2 | $569K | Buy |
+60,539
| New | +$569K | ﹤0.01% | 4169 |
|